Get Real! The Rise of Observational Data In Healthcare

safety across the treated patient population for pharmacovigilance purposes and can also provide additional pharmacoeconomic insights, for example looking at the use of resources or financial considerations. ... Pfizer recently set up a specialised unit -

Antibiotics: pharma's Cinderella story

Finally, can the agents which promise rapid infection resolution and the potential of patient management outside the hospital setting create compelling pharmacoeconomic arguments to justify premium pricing?

Questions raised about affordability of asthma antibodies

GSK meanwhile says it is confident that pharmacoeconomic studies will prove the worth of biologics in reducing hospitalisations and the significant morbidity associated with oral steroid use.

Genzyme continues MS drug rollout across EU

The launch of Lemtrada follows a recommendation in July this year from the National Centre for Pharmacoeconomics (NCPE), which provides guidance on what drugs should be reimbursed on Ireland's healthcare

Taking contract research’s pulse

They are also seeing increased demand for pharmacoeconomic end points in trials and comparative effectiveness research (CER) to help meet payers' increasing demands on patient outcomes.

Health technology assessments: understanding the global landscape and considerations for drug development

Other markets combine the relative medical advancement with the incremental increase in cost into one assessment through pharmacoeconomic modelling. ... This will provide insights around the price ranges that will be considered cost-effective by payers

Drug safety

Drug pricing

Healthcare systems

Finance and investment

Fishawack Health expands its value, evidence, and market access capabilities with the acquisition of HEOR consultancy Policy Analysis Inc. (PAI)

pharmacoeconomics, outcomes research, quality-of-life assessment, pharmacoepidemiology, and health technology assessment.

WHITE PAPER: Patient nonadherence – the $637bn paradox

compliance with interventions supported by electronic monitoring devices. Pharmacoeconomics 2007; 25(8):621–635.

Plugging knowledge gaps to demonstrate the benefits of new medicines

Hayward Medical Communications recently presented a poster, titled The use of consensus techniques to inform health technology appraisals, at the 19th Annual European Conference of the International Society for Pharmacoeconomics and